Close Menu

NEW YORK (GenomeWeb News) – Investment bank Jefferies today upgraded shares of Sequenom to Buy following a survey of US commercial payors that suggests the San Diego-based firm is gaining "meaningful traction" in getting coverage for its MaterniT21 Plus LDT test.

Jefferies upgraded Sequenom's shares from Hold and maintained the price target on its shares at $7.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.